John O. Mascarenhas, MD - Optimizing JAK Inhibitor Therapy for Patients With Myelofibrosis: Integrating New and Emerging Therapies Into the Current Treatment Paradigm

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Living Breakthrough-Minded | Joel Osteen 30 min · 25 Sep 2026 · Joel Osteen Podcast

4AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Week: Trump vs the Press, Meta’s AI Win, and the Turning Political Tide 22 min · 25 Sep 2026 · The Prof G Pod with Scott Galloway

Gabrielle Lyon Part 2 1h 1m · 25 Sep 2026 · unPAUSED with Dr. Mary Claire Haver

Report any issue

Source

Recorded04 May 2023

Publisherc.answersincme.com ↗

Handlerec:766087

Show notes

Please visit answersincme.com/BCJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses JAK inhibitor therapy for patients with myelofibrosis. Upon completion of this activity, participants should be better able to: Identify early signs of ruxolitinib failure for timely risk stratification of patients with myelofibrosis (MF); Describe the clinical profiles of novel JAK inhibitors for the treatment of patients with MF; and Outline evidence-based strategies to optimize JAK inhibitor therapy for patients with MF.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in